SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Nephrocare Health Services Ltd (NEPHROPLUS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544647 NSE: NEPHROPLUS Hospital & Healthcare Services | Small Cap | Nephrocare Health Se Share Price

₹661.30 1.50 (0.23%)

As on 04-Jun'26 16:59

Nephrocare Health Services Ltd (NEPHROPLUS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544647 NSE: NEPHROPLUS Hospital & Healthcare Services | Small Cap | Nephrocare Health Se Share Price

₹661.30 1.50 (0.23%)

As on 04-Jun'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹6,636 Cr.
Current Price
₹661.3
52-Week Low / High
₹445 / 671
TTM EPS
₹-0.8
TTM Sales
₹630 Cr.
Book Value per Share
₹96.8
P/E Ratio
0.00
Lower than its 5-year historical median
Industry PE
87
Price to Book (P/B)
6.83
Higher than its 5-year historical median
Price to Sales (P/S)
10.54
Higher than its 5-year historical median
EV/EBITDA
61.90
Higher than its 5-year historical median
Dividend Yield
0.00%
Profitability Efficiency
Return on Equity (ROE)
7.44%
Underperforms industry median
Return on Capital Employed (ROCE)
9.56%
Underperforms industry median
Return on Assets (ROA)
4.95%
Operating Profit Margin
17.5%
Net Profit Margin
6.3%
Gross Profit Margin
17.7%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
24.61%
Operating Profit Growth (1 Year)
-
82.6%
Net Profit Growth (1 Year)
-
782.47%
Asset Quality
Promoter Holding
63.85%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹951 Cr.
Equity
₹20.1 Cr.
Face Value
₹2
All Time Low / High
₹445.00 / 670.55

Nephrocare Health Services stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Not Good
Check detailed performance

Valuation

Overvalued

Check Valuation charts

Price Trend

Strong
Check Price chart
Q.1 Is Nephrocare Health Services Ltd a good quality company?
Nephrocare Health Services Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Nephrocare Health Services Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Nephrocare Health Services Ltd vs industry peers?
Nephrocare Health Services Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 6.53%, indicating slower growth and losing its market share.
Q.1 Promoter shareholding and pledge status of Nephrocare Health Services Ltd?
Promoters hold 63.85% of the Nephrocare Health Services Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Nephrocare Health Services Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.
View More

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Nephrocare Health Services Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation ⓘ

Mar'23Mar'24Mar'25TTM
ROCE % ⓘ0.4%2.9%9.6%-
Value Creation
Index ⓘ		-1.0-0.8-0.3-

Growth Parameters ⓘ
Sales ⓘ386436544630
Sales YoY Gr.-13%24.6%-
Adj EPS ⓘ-15.64.732.4-0.8
YoY Gr.-NA587.1%-
BVPS (₹) ⓘ442.7451.1595.896.8
Adj Net
Profit ⓘ		-15.74.933.8-8
Cash Flow from Ops. ⓘ11.156.879.7-
Debt/CF from Ops. ⓘ17.63.11.5-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘNANANA24.6%
Adj EPS ⓘNANANA587.1%
BVPSⓘNANANA32.1%
Share Price - - - -

Key Financial Parameters ⓘ

Mar'23Mar'24Mar'25TTM
Return on
Equity % ⓘ		-41.27.2-0.2
Op. Profit
Mgn % ⓘ		9.812.217.514.7
Net Profit
Mgn % ⓘ		-4.11.16.2-1.3
Debt to
Equity ⓘ		0.50.50.20
Working Cap
Days ⓘ		0243178139
Cash Conv.
Cycle ⓘ		01038495

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25
Sales386436544
Operating Expenses ⓘ + 348384449
Manufacturing Costs103136171
Material Costs133139149
Employee Cost 857293
Other Costs ⓘ 273835
Operating Profit ⓘ 385295
Operating Profit Margin (%) 9.8%11.9%17.5%
Other Income ⓘ + 5816
Exceptional Items ⓘ 000
Interest ⓘ 151714
Depreciation ⓘ 414351
Profit Before Tax ⓘ -13045
Tax ⓘ 3-411
Profit After Tax -15434
PAT Margin (%) -4.0%0.9%6.3%
Adjusted EPS (₹)-17.84.438.8
Dividend Payout Ratio (%)0%0%0%

Valuation of Nephrocare Health Se - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 389398529
Share Capital ⓘ 555
Reserves ⓘ 383393524
Debt +173157106
Long Term Debt816446
Short Term Debt929360
Minority Interest000
Trade Payables144161
Others Liabilities ⓘ 544842
Total Liabilities ⓘ 630644739

Fixed Assets

Net Fixed Assets ⓘ +169219234
Gross Block308397455
Accumulated Depreciation139178221
CWIP ⓘ 314
Investments ⓘ 148149212
Inventories221918
Trade Receivables129138194
Cash Equivalents 3233
Others Assets ⓘ 15611743
Total Assets ⓘ 630644739

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'23Mar'24Mar'25
Cash Flow From Operating Activity ⓘ + 115780
PBT ⓘ -13045
Adjustment ⓘ 576461
Changes in Working Capital ⓘ -37-2-30
Tax Paid ⓘ 4-63
Cash Flow From Investing Activity ⓘ + -75-23-104
Capex -39-74-81
Net Investments -546-25
Others ⓘ -3162
Cash Flow From Financing Activity ⓘ + 63-3626
Net Proceeds from Shares ⓘ -1198
Net Proceeds from Borrowing ⓘ 19-19-22
Interest Paid ⓘ -15-17-14
Dividend Paid ⓘ 000
Others ⓘ 60-1-36
Net Cash Flow ⓘ -0-12

Financial Ratio

PARTICULARSMar'23Mar'24Mar'25
Ratios
ROE (%)-4.0217.44
ROCE (%)0.362.99.56
Asset Turnover Ratio0.610.690.79
PAT to CFO Conversion(x)N/A14.252.35
Working Capital Days
Receivable Days122111.80111.40
Inventory Days2117.3012.40
Payable Days39.8072.90124.90

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Nephrocare Health Services Ltd FAQs

The current trading price of Nephrocare Health Se on 04-Jun-2026 16:59 is ₹661.3.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Nephrocare Health Se stood at ₹6,635.5 Cr

The latest P/E ratio of Nephrocare Health Se as of 03-Jun-2026 is 0.00.

The latest P/B ratio of Nephrocare Health Se as of 03-Jun-2026 is 6.83.

The 52-week high of Nephrocare Health Se is ₹670.5 and the 52-week low is ₹445.0.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Nephrocare Health Se is ₹630 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Nephrocare Health Services Ltd is a below average quality company.

The key valuation ratios of Nephrocare Health Services Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Nephrocare Health Services Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Nephrocare Health Services Ltd

Nephrocare Health Services was incorporated as ‘Nephrocare Health Services Private Limited’ on December 18, 2009. Pursuant to resolutions dated April 11, 2025 and June 2, 2025 passed by its Board and Shareholders, respectively, the company was converted into a public limited company and consequently, the name of the company was changed to ‘Nephrocare Health Services Limited’ on June 18, 2025.

It offers comprehensive dialysis care through its network of clinics - from diagnosis to treatment and wellness programs including haemodialysis, home and mobile dialysis, supported by pharmacy. It has a global network of over hundreds of clinics and has the most widely distributed dialysis network in India with an extensive pan-India network of clinics across hundreds of cities and many States and several Union Territories. Its widespread presence ensures patients have easy accessibility to dialysis services.

It enhances patient accessibility by operating its network of clinics across various formats including in-hospital captive clinics, standalone clinics, and government-backed public private partnerships (PPPs) - enabling it to serve patients in private hospitals and government facilities. It operates a scalable, asset-light and capital efficient business model, which helps ensure quick clinic additions and ramp-ups with low capital expenditure, as well as a high return on capital employed, economies of scale and strong unit economics.

Business area of the company

Nephrocare Health Services is engaged in offering comprehensive dialysis care through its network of clinics - from diagnosis to treatment and wellness programs including haemodialysis, home and mobile dialysis, supported by pharmacy. Its widespread presence ensures patients have easy accessibility to dialysis services.

Services of the company

Dialysis Services

  • Haemodialysis
  • Peritoneal dialysis

In-Clinic Dialysis Services

  • Captive Model through Arrangements with Hospitals
  • Standalone clinics 
  • Public-Private Partnership (PPP) clinics

Off-Clinic Dialysis Services

  • Home haemodialysis (HHD)
  • Dialysis on call (DoC)
  • Dialysis on wheel (DoW)

Awards and recognitions

  • 2017: Awarded the Business Models Innovation Awards for the Best Medical Services Outsourcer at HBI Business Model Innovation Awards by Healthcare Business International in association with KPMG 
  • 2019: Awarded the Indian Dialysis Service Provider Company of the Year Award 2019 by Frost and Sullivan 
  • 2022: Awarded the Single Specialty Hospital of the Year award by the grand jury of the 12th MT India Healthcare Awards 2022 and Medgate Today magazine 
  • 2024: Awarded the “Innovation in Health” award at the 14th edition of Aegis Graham Bell Awards 
  • 2025: Received the Guinness World Records for the most people to sign-up for a kidney screening online in one week 
  • 2025: Received the India Book of Records for maximum people screened for serum creatinine test held at multiple venues 
  • 2025: Awarded the “Dialysis Chain of the Year - National” award at the Economic Times Healthcare Awards 2025

History and millstones

  • 2010: Launched its first standalone clinic in Banjara Hills, Hyderabad, India. 
  • 2012: Launched its first Public Private Partnership (PPP) clinic in Sananth Nagar, Hyderabad, India 
  • 2015: Launched 50th dialysis clinic and crossed 10,000 plus treatments per month 
  • 2018: Acquired DaVita Care (India) Private Limited, the Indian arm of DaVita Care Pte Ltd. 
  • 2020: Launched operations in Philippines by acquiring Royal Care Dialysis Center, Inc 
  • 2022: Launched operations in Uzbekistan after the award of PPP tender. 
  • 2024: Acquired a network of six clinics in Philippines pursuant to the acquisition of Renal Therapy Solutions Inc. 
  • 2025: Acquired and a chain of seven clinics (AIZ Hemodialysis Center Inc., Bioregen Hemo Center Inc., Carmona Dialysis System Inc., Infini Care Health Systems Inc., and Kolff Dialysis Inc.) 
  • 2025: Crossed 500 plus clinic globally.

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×